The DOI matches its Crossref record.
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Caplin, M. E., Baudin, E., Ferolla, P., Filosso, P., Garcia-Yuste, M., Lim, E., Oberg, K., Pelosi, G., Perren, A., Rossi, R. E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv041 · Cited by 714
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Neuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
Steinmüller, T., Kianmanesh, R., Falconi, M., Scarpa, A., Taal, B., Kwekkeboom, D. J., Lopes, J. M., Perren, A., Nikou, G., Yao, J., et al. (2008) · Neuroendocrinology · doi:10.1159/000111037 · Cited by 296
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/154541 · Cited by 69
“Platinum-based chemotherapy regimens may be useful in patients with high-grade, poorly differentiated NETs, with response rates of 42% to 80% with the use of cisplatin and etoposide [54–56], and 78% with use of oxaliplatin-based regimens [57].”
Background
Metadata
- Authors
- Bajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., Martinetti, A., Platania, M., Verzoni, E., Formisano, B., & Bajetta, R.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2006-08-26
- Volume
- 59
- Issue
- 5
- Pages
- 637-642
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2042265119
- Cited by
- 240
- References
- 0
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.